Bing Z. Carter, Ph.D.

Peer-Reviewed Articles

1. Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
2. Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5. e-Pub 2024. PMID: 38856690.
3. Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):729-740, 2024. e-Pub 2023. PMID: 38148395.
4. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Correction. Blood Cancer J 13(1):80, 2023. PMID: 37193700.
5. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv 9(48):eadh1436, 2023. e-Pub 2023. PMID: 38019903.
6. Ebner J, Schmoellerl J, Piontek M, Manhart G, Troester S, Carter BZ, Neubauer H, Moriggl R, Szakács G, Zuber J, Köcher T, Andreeff M, Sperr WR, Valent P, Grebien F. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. Nat Commun 14(1):5709, 2023. e-Pub 2023. PMID: 37726279.
7. Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica 108(9):2513-2519, 2023. e-Pub 2023. PMID: 36727398.
8. Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood 142(12):1056-1070, 2023. e-Pub 2023. PMID: 37339579.
9. Xie C, Zhou H, Qin D, Zheng H, Tang Y, Li W, Zhou J, Liu L, Yu X, Duan H, Zhou Y, Li Z, Fang Z, Luo Y, Carter BZ, Xu B, Zha J. Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia. Cell Death Dis 14(8):573, 2023. e-Pub 2023. PMID: 37644011.
10. Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, Lee S, Lasry A, Sun Z, Papaioannou D, Cammer M, Wang K, Zal T, Zal MA, Carter BZ, Ishizawa J, Tibes R, Tsirigos A, Andreeff M, Gavathiotis E, Aifantis I. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia. Cancer Discov 13(7):1656-1677, 2023. e-Pub 2023. PMID: 37088914.
11. Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J 13(1):57, 2023. e-Pub 2023. PMID: 37088806.
12. Saxena K, Carter BZ, Konopleva M. EXABS-147-AML How Do We Overcome Resistance to Venetoclax. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S55-S57, 2022. PMID: 36164229.
13. Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo VR, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S218, 2022. PMID: 36163775.
14. Akiyama H, Zhao R, Nishida Y, Ostermann L, Mak PY, Ayoub E, Piya S, Carter B, Andreeff M, Ishizawa J. AML-250 Mitochondrial Respiration Regulates GPX4 Inhibition-Induced Ferroptosis in Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S229, 2022. PMID: 36163797.
15. Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica 107(6):1311-1322, 2022. e-Pub 2022. PMID: 34732043.
16. Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour EJ, Hughes PE, Chen X, Morrow PK, Andreeff M. Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol Cancer Ther 21(6):879-889, 2022. e-Pub 2022. PMID: 35364607.
17. Chen Q, Deng S, Deng M, Shi Y, Zhong M, Ding L, Jiang Y, Zhou Y, Carter BZ, Xu B. Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways. Exp Hematol Oncol 11(1):23, 2022. e-Pub 2022. PMID: 35429966.
18. Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Hayashizaki Y, Carter BZ, Tabe Y, Andreeff M. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Transl Oncol 18:101354, 2022. e-Pub 2022. PMID: 35114569.
19. Wang Y, Carter BZ, Li Z, Huang X. Application of machine learning methods in clinical trials for precision medicine. JAMIA Open 5(1):ooab107, 2022. e-Pub 2022. PMID: 35178503.
20. Carter BZ, Tao W, Mak PY, Ostermann LB, Mak D, McGeehan G, Ordentlich P, Andreeff M. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood 138(17):1637-1641, 2021. e-Pub 2021. PMID: 34232981.
21. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. PMID: 34424319.
22. Jiang X, Jiang L, Cheng J, Chen F, Ni J, Yin C, Wang Q, Wang Z, Fang D, Yi Z, Yu G, Zhong Q, Carter BZ, Meng F. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. J Transl Med 19(1):117, 2021. e-Pub 2021. PMID: 33743723.
23. Lovat F, Gasparini P, Nigita G, Larkin K, Byrd JC, Minden MD, Andreeff M, Carter BZ, Croce CM. Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc Natl Acad Sci U S A 118(11), 2021. PMID: 33836616.
24. Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Targeting MCL-1 Dysregulates Cell Metabolism and Leukemia-stroma Interactions and Re-sensitizes acute myeloid leukemia to BCL-2 Inhibition. Haematologica Online ahead of print(1):58-76, 2020. e-Pub 2020. PMID: 33353284.
25. He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother 129:110390, 2020. e-Pub 2020. PMID: 32563150.
26. Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, Ruvolo V, Pachter JA, Weaver DT, Andreeff M, Xu B, Carter BZ. Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances anti-leukemia activity of venetoclax in acute myeloid leukemia. Mol Cancer Ther 19(8):1636-1648, 2020. e-Pub 2020. PMID: 32404407.
27. Shi YF, Liu L, He LL, Ye J, Lin ZJ, Yuan DL, Deng MM, Fang ZH, Carter BZ, Xu B. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis 11(7):555, 2020. e-Pub 2020. PMID: 32699295.
28. Carter BZ, Mak PY, Mu H, Wang X, Tao W, Mak DH, Dettman EJ, Cardone M, Zernovak O, Seki T, Andreeff M. Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica 105(5):1274-1284, 2020. e-Pub 2019. PMID: 31371419.
29. Chen F, Sun J, Yin C, Cheng J, Ni J, Jiang L, Wang Q, Yu G, Wei Y, Liu X, Sun J, Carter BZ, Jiang X. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation. Bone Marrow Transplant 55(4):740-748, 2020. e-Pub 2019. PMID: 31645666.
30. Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, Halene S, Xu T, Rothberg J, Lichenstein H. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv 3(22):3661-3673, 2019. PMID: 31751472.
31. Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M. An ARC-regulated IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Cancer Res 79(6):1165-1177, 2019. e-Pub 2019. PMID: 30674535.
32. Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/β-catenin exerts anti-leukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia. Clin Cancer Res 24(10):2417-2429, 2018. e-Pub 2018. PMID: 29463558.
33. Goethe E, Carter BZ, Rao G, Pemmaraju N. Glioblastoma and Acute Myeloid Leukemia: Malignancies with Striking Similarities. J Neurooncol 136(2):223-231, 2018. e-Pub 2017. PMID: 29196926.
34. Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak DH, Mu H, Ruvolo VR, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16(6):1133-1144, 2017. e-Pub 2017. PMID: 28270436.
35. Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Liu Q, Andreeff M, Carter BZ. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. e-Pub 2017. PMID: 28321124.
36. Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, Carter BZ, Wang X, Shi X, Liu J. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. J Hematol Oncol 9(1):129, 2016. e-Pub 2016. PMID: 27884201.
37. Fang ZH, Wang SL, Zhao JT, Lin ZJ, Chen LY, Su R, Xie ST, Carter BZ, Xu B. mir-150 Exerts Antileukemia Activity in vitro and in vivo through Regulating Genes in Multiple Pathways. Cell Death Dis 7(doi:10.1038):e2371, 2016. e-Pub 2016. PMID: 27899822.
38. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting of BCL-2 and Bcr-Abl Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem Cells. Sci Transl Med 8(355):355ra117, 2016. PMID: 27605552.
39. Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med 13(2):248-59, 2016. PMID: 27458532.
40. Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget 7(15):20054-67, 2016. e-Pub 2016. PMID: 26956049.
41. Jiang X, Wang Z, Ding B, Yin C, Zhong Q, Carter BZ, Yu G, Jiang L, Ye J, Dai M, Zhang Y, Liang S, Zhao Q, Liu Q, Meng F. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget 6(32):33612-22, 2015. e-Pub 2015. PMID: 26384351.
42. Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget 6(31):30487-99, 2015. e-Pub 2015. PMID: 26431162.
43. Carter BZ, Andreeff M. Targeting AML stem/progenitor cells by combinational therapy with SMAC mimetics and demethylating agents. Stem Cell Epigenetics:1-6. e-Pub 2015. PMID: None.
44. Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Kantarjian H, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signaling in acute myeloid leukaemia. Br J Haematol 167(3):376-84, 2014. e-Pub 2014. PMID: 25079338.
45. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, Dou QP, Wang X, Liu J. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget 5(19):9118-32, 2014. e-Pub 2014. PMID: 25193854.
46. Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol 73(5):961-74, 2014. e-Pub 2014. PMID: 24619497.
47. Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by MAPK/PI3K and Confers Drug Resistance and Survival Advantage to AML. Apoptosis 19(4):698-707, 2014. e-Pub 2013. PMID: 24337870.
48. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, Mu H, Tibes R, Yao H, Coombes KR, Jacamo RO, McQueen T, Kornblau SM, Andreeff M. Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents. J Natl Cancer Inst 106(2):djt440, 2014. PMID: 24526787.
49. Shi X, Lan X, Li X, Chen X, Carter BZ, Wang X, Liu J. 2-tert-butyl-1,4-benzoquinone Induces Apoptosis in Chronic Myeloid Leukemia Cells Resistant to Imatinib via Inducing Caspase-dependent Bcr-Abl Downregulation. Med Chem 4(12):786-790, 2014. PMID: None.
50. Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE. XIAP Downregulation Promotes Caspase-dependent Inhibition of Proteasome Activity in AML Cells. Leuk Res 37(8):974-9, 2013. e-Pub 2013. PMID: 23669290.
51. Katragadda L, Carter BZ, Borthakur G. XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs 22(5):663-70, 2013. PMID: 23586880.
52. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120(1):173-80, 2012. e-Pub 2012. PMID: 22645176.
53. Mak DH, Wang RY, Schober WD, Konopleva M, Cortes J, Kantarjian H, Andreeff M, Carter BZ. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia doi:10.1038(4):788-94, 2012. e-Pub 2011. PMID: 22033489.
54. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 26(3):443-50, 2012. e-Pub 2011. PMID: 21904380.
55. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117(3):780-7, 2011. e-Pub 2010. PMID: 21041716.
56. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16(1):67-74, 2011. e-Pub 2010. PMID: 20938744.
57. Le XF, Mao W, Lu Z, Carter BZ, Bast RC. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980-90, 2010. e-Pub 2010. PMID: 20629079.
58. Samudio I, Konopleva M, Carter BZ, Andreeff M. Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res 145:197-217, 2010. PMID: 20306253.
59. Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 115(2):306-14, 2010. e-Pub 2009. PMID: 19897582.
60. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 23(10):1755-62, 2009. e-Pub 2009. PMID: 19458629.
61. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 27(28):4741-6, 2009. e-Pub 2009. PMID: 19652057.
62. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 8(9):2509-16, 2009. e-Pub 2009. PMID: 19723894.
63. Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I. Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 16(5):886-92, 2008. e-Pub 2008. PMID: 18388920.
64. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111(7):3742-50, 2008. e-Pub 2008. PMID: 18187663.
65. Mak DH, Schober WD, Chen W, Heller J, Andreeff M, Carter BZ. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma 48(4):774-85, 2007. PMID: 17454637.
66. Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood 109(5):2121-9, 2007. e-Pub 2006. PMID: 17077328.
67. Sah NK, Munshi A, Hobbs M, Carter BZ, Andreeff M, Meyn RE. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys 66(3):852-9, 2006. PMID: 17011457.
68. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 5(19):2223-9, 2006. e-Pub 2006. PMID: 16969080.
69. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, Altieri DC. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98(15):1068-77, 2006. PMID: 16882944.
70. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 108(2):630-7, 2006. e-Pub 2006. PMID: 16556893.
71. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 107(4):1555-63, 2006. e-Pub 2005. PMID: 16254145.
72. Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Pond GR, Mawji IA, Houghten RA, Ostresh J, Brandwein J, Minden MD, Schuh AC, Wells RA, Messner H, Chun K, Reed JC, Schimmer AD. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105(10):4043-50, 2005. e-Pub 2005. PMID: 15687241.
73. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol 83 Suppl 1:S51-3, 2004. PMID: 15124670.
74. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M, Sung HG, Reed JC, Andreeff M. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 102(12):4179-86, 2003. e-Pub 2003. PMID: 12920030.
75. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17(11):2081-9, 2003. PMID: 12970762.
76. Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2(5):488-93, 2003. PMID: 12963850.
77. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 99(9):3461-4, 2002. PMID: 11964319.
78. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 108(6):851-9, 2001. PMID: 11560954.
79. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 97(9):2784-90, 2001. PMID: 11313272.
80. Lieberman MW, Shields JE, Will Y, Reed DJ, Carter BZ. Gamma-glutamyl leukotrienase cleavage of leukotriene C4. Adv Exp Med Biol 469:301-6, 1999. PMID: 10667345.
81. Carter BZ, Shi ZZ, Barrios R, Lieberman MW. gamma-glutamyl leukotrienase, a gamma-glutamyl transpeptidase gene family member, is expressed primarily in spleen. J Biol Chem 273(43):28277-85, 1998. PMID: 9774450.
82. Carter BZ, Wiseman AL, Orkiszewski R, Ballard KD, Ou CN, Lieberman MW. Metabolism of leukotriene C4 in gamma-glutamyl transpeptidase-deficient mice. J Biol Chem 272(19):12305-10, 1997. PMID: 9139674.
83. Lieberman MW, Wiseman AL, Shi ZZ, Carter BZ, Barrios R, Ou CN, Chévez-Barrios P, Wang Y, Habib GM, Goodman JC, Huang SL, Lebovitz RM, Matzuk MM. Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice. Proc Natl Acad Sci U S A 93(15):7923-6, 1996. PMID: 8755578.
84. Shi ZZ, Carter BZ, Habib GM, He X, Sazer S, Lebovitz RM, Lieberman MW. A single mouse glutathione synthetase gene encodes six mRNAs with different 5' ends. Arch Biochem Biophys 331(2):215-24, 1996. PMID: 8660701.
85. Habib GM, Carter BZ, Sepulveda AR, Shi ZZ, Wan DF, Lebovitz RM, Lieberman MW. Identification of a sixth promoter that directs the transcription of gamma-glutamyl transpeptidase type III RNA in mouse. J Biol Chem 270(23):13711-5, 1995. PMID: 7775425.
86. Carter BZ, Habib GM, Shi ZZ, Sepulveda AR, Lebovitz RM, Lieberman MW. Rat small intestine expresses primarily type VI gamma-glutamyl transpeptidase RNA. Biochem Mol Biol Int 35(6):1323-30, 1995. PMID: 7492970.
87. Carter BZ, Habib GM, Sepulveda AR, Barrios R, Wan DF, Lebovitz RM, Lieberman MW. Type VI RNA is the major gamma-glutamyl transpeptidase RNA in the mouse small intestine. J Biol Chem 269(40):24581-5, 1994. PMID: 7523374.
88. Sepulveda AR, Carter BZ, Habib GM, Lebovitz RM, Lieberman MW. The mouse gamma-glutamyl transpeptidase gene is transcribed from at least five separate promoters. J Biol Chem 269(14):10699-705, 1994. PMID: 7908294.
89. Carter BZ, Li SC, Li YT. Ceramide glycanase from the earthworm, Lumbricus terrestris. Biochem J 285 (Pt 2):619-23, 1992. PMID: 1637351.
90. Stephens JM, Carter BZ, Pekala PH, Malter JS. Tumor necrosis factor alpha-induced glucose transporter (GLUT-1) mRNA stabilization in 3T3-L1 preadipocytes. Regulation by the adenosine-uridine binding factor. J Biol Chem 267(12):8336-41, 1992. PMID: 1314824.
91. Li YT, Carter BZ, Rao BN, Schweingruber H, Li SC. Synthesis of neoglycoconjugates using oligosaccharide transferring activity of ceramide glycanase. J Biol Chem 266(17):10723-6, 1991. PMID: 2040590.
92. Zhou B, Li SC, Laine RA, Huang RT, Li YT. Isolation and characterization of ceramide glycanase from the leech, Macrobdella decora. J Biol Chem 264(21):12272-7, 1989. PMID: 2745442.

Invited Articles

1. Katragadda L, Carter BZ, Borthakur G. XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs 22(5):663-70, 2013. PMID: None.
2. Carter BZ, Mak DH, Cortes J, Andreeff M. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?. Semin Hematol 47(4):362-70, 2010. PMID: 20875553.
3. Carter BZ, Andreeff M. Targeting survivin in leukemia. Oncol Rev 2:19-28, 2008. PMID: None.

Other Articles

1. Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, DiNardo CD, Kadia TM, Guest E, Short NJ, McCall D, Daver N, Nunez C, Haddad FG, Garcia M, Bhalla KN, Maiti A, Catueno S, Fiskus W, Carter BZ, Gibson A, Roth M, Khazal S, Tewari P, Abbas HA, Bourgeois W, Andreeff M, Shukla NN, Truong DD, Connors J, Ludwig JA, Stutterheim J, Salzer E, Juul-Dam KL, Sasaki K, Mahadeo KM, Tasian SK, Borthakur G, Dickson S, Jain N, Jabbour E, Meshinchi S, Garcia-Manero G, Ravandi F, Stein EM, Kolb EA, Issa GC Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia 38(10):2073-2084, 2024. PMID: 39179671.
2. Akiyama, H, Zhao, R, Ostermann, LB, Li, Z, Tcheng, M, Yazdani, SJ, Moayed, A, Pryor, ML, Slngh, S, Baran, N, Ayoub, E, Nishida, Y, Mak, PY, Ruvolo, VR, Carter, BZ, Schimmer, AD, Andreeff, M, Ishizawa, J Correction to. Leukemia 38(4):926, 2024. PMID: 38459170.
3. Akiyama H, Carter BZ, Andreeff M, Ishizawa J Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia. Cells 12(8), 2023. PMID: 37190037.
4. Maiti A, Carter BZ, Andreeff M, Konopleva MY Beyond BCL-2 Inhibition in Acute Myeloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk 22(9):652-658, 2022. PMID: 35490155.
5. Boddu P, Carter BZ, Verstovsek S, Pemmaraju N SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol 185(2):219-231, 2019. PMID: 30836448.
6. Lieberman MW, Barrios R, Carter BZ, Habib GM, Lebovitz RM, Rajagopalan S, Sepulveda AR, Shi ZZ, Wan DF gamma-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions?. Am J Pathol 147(5):1175-85, 1995. PMID: 7485380.
7. Carter BZ, Malter JS Regulation of mRNA stability and its relevance to disease. Lab Invest 65(6):610-21, 1991. PMID: 1753708.

Editorials

1. Carter BZ, Andreeff M. Eradication of CML stem cells. Oncoscience 3(11-12):313-315, 2016. PMID: 28105453.

Abstracts

1. Kamachi K, Akiyama H, Otsuki Y, Zhao R, Zhang L, Ostermann L, Carter B, Saya H, Nagano O, Andreeff M, Ishizawa J. Targeting Ferroptosis-Apoptosis Interplay For Acute Myeloid Leukemia Therapy. Japanese Society of Hematology, 2024. PMID: None.
2. Nishida Y, Ayoub E, Baran N, Mizuno H, Khazaei S, Ostermann L, Munir, Ke B, Mak PY, Carter BZ, Impedovo V, Tiziani S, Haferlach T, Maiti A, Mohanty V, Chen K, Ma L, Andreeff M. TARGETING MYC BY DEGRADATION REWIRES METABOLOMICS AND INDUCES CELL KILL IN TP53 MUTANT ACUTE MYELOID LEUKEMIAS. European Hematology Association, 2024. PMID: None.
3. Carter BZ, Mak PY, Ke B, Boettcher S, Bedoy AD, Ostermann LB, Gener-Ricos G, DiNardo C, Puzio-Kuter A, Levine A, Andreeff M. Enhancing the efficacy of p53-Y220C reactivator PC14586 by combination with MDM2 or BCL-2 inhibitors in TP53-Y220C AML. European Hematology Association, 2024. PMID: None.
4. Andreeff M, Nishida Y, Ayoub E, Baran N, Gener Ricos G, Impedovo V, Tiziani S, DiNardo C, Ma L, Puzio-Kuter A, Levine A, Carter BZ. Targeting Mutant p53 Acute Myeloid Leukemias (AML) by Conformational Reactivation of Y220C mutant p53 and by Degradation of Upregulated c-MYC. First Asia Pacific Symposium on AML, University of Hong Kong, 2024. PMID: None.
5. Nishida Y, Ayoub E, Scruggs D, Khazaei S, Munir, F, Ostermann LB, Mak PY, Baozhen K, Carter BZ, Baran N, Maiti A, Mohanty V, Chen K, Navin N, Haferlach T, Ren Z, Tong Y, Chen D, Issa GC, Andreeff M. Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC. Blood 142, 2023. PMID: None.
6. Gener-Ricos G, Bewersdorf JP, Loghavi S, Goldberg AD, Famulare C, Issa GC, Borthakur G, Kadia TM, Carter BZ, Patel KP, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C Mutations in Patients with Myeloid Malignancies. Blood 142, 2023. PMID: None.
7. Sharma P, Ostermann LB, Piya S, Ke B, Baran N, Tyagi A, Muftuoglu M, Basyal M, Zhang Q, Munck J, K-H D, Sims M, Carter BZ, Battula VL, Andreeff M, Borthakur G. ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission. Blood 142, 2023. PMID: None.
8. Carter BZ, Mak PY, Ke B, Bedoy A Boettcher S, Ostermann LB, Shpall EJ, Andreeff M. Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML. Blood 142, 2023. PMID: None.
9. Muftuoglu M, Basyal M, Li L, Lv J, Ostermann LB, Zhao R, Ke, B Akiyama H, Mak PY, Carter BZ, H, Li Y, Garrison BS, Rajangam KL, Andreeff M. Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models. Blood 142, 2023. PMID: None.
10. Akiyama H, Tcheng M, Sharma P, Zhao R, Ostermann LB, Yazdani S, Moayed A, Szulc Z, Oleinik N, Mak PY, Ruvolo V, Carter BZ, Ogretmen B, Borthakur G, Schimmer AD, Andreeff M, Ishizawa J. Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia. Blood 142, 2023. PMID: None.
11. Carter BZ, Mak PY, Ke B, Nishida Y, Boettcher S, Bedoy A, Ostermann LB, DiNardo CD, Puzio-Kuter A, Levine A, Andreeff M. Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2. Blood 142, 2023. PMID: None.
12. Carter BZ, Mak PY, Ke B, Bedoy AD, Ostermann LB, DiNardo C, Puzio-Kuter A, Levine A, Andreeff M. Activation of p53 in TP53-Y220C Mutant Acute Myeloid Leukemia by PC14586 and Synergistic Induction of Apoptosis by Concomitant MDM2 Inhibition. MDM2 Workshop, Tokyo, 2023. PMID: None.
13. Quezada Meza CP, Borgo C, Salizzato V, Zavatti M, Marmiroli S, Carter BZ, Donella A, Ruzzene M. CK2 plays a critical role in tyrosine kinase inhibitor resistance driven by the Bcr-Abl T315I mutation in chronic myeloid leukemia. The 47th FEBS Congress, 2023. PMID: None.
14. Carter BZ, Mak PY, Tao W, Muftuoglu M, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Basyal M, Pemmaraju N, Boettcher S, Shpall EJ, Wallner B, Morgan RA, Andreeff MA. Epichaperome Targeting Induces Profound Apoptotic Cell Death in TP53-Mutant Cells and Ste/Progenitor Cells in AML. EECDO - EATI Annual Meeting, Paris, 2023. PMID: None.
15. Carter BZ, Mak PY, Tao W, Ostermann L, Mak D, Ke B, Issa G, Ordentlich P, McGeehan G, Andreeff M. Combined menin/flt3/bcl-2 inhibition is potentially curative in npm1/flt3-itd/-tkd mutant aml. Acute Leukemias XVIII - ISALXVIII Biology and Treatment Strategies, 2023. PMID: None.
16. Carter BZ, Mak PY, Tao W, Ostermann LB, Nishida Y, Boettcher S, Andreeff M. Targeting HSP90 epichaperome in TP53 mutant AML. 2023 AACR Special Conference: AML and Myelodysplastic Syndrome, 2023. PMID: None.
17. Andreeff M, Chang KH, Ji Y, Muftuoglu M, Mak PY, Basyal M, Ostermann, LB, Burks JK, Ly C, Mu H, Fogler WE, Magnani JL, Lesegretaom A, Zal MA, Zal T, Carter BZ, Zhang W. Combinatorial CXCR4/E-Selectin Inhibition is Required to Overcome Microenvironment-Mediated Resistance to BCL-2 and FLT3-targeted Therapies in Acute Myeloid Leukemias. ESH Microenvironment Conference, 2023. PMID: None.
18. Nishida Y, Scruggs DA, Ayoub E, Patsilevas T, Ruvolo V, Mak PY, Carter BZ, Boettcher S, Maiti A, Zhou Q, Yang Z, Yan H, Ma L, Andreeff M. C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas. Blood 140, 2022. PMID: None.
19. Carter BZ, Mak PY, Tao W, Ostermann LB, Nishida Y, Pemmaraju N, Boettcher S, Shpall EJ, Chiosis G, Karras G, Wallner B, Morgan RA, Andreeff M. Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML. Blood 140, 2022. PMID: None.
20. Carter BZ, Mak PY, Tao W, Ostermann LB, Mak D, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3-ITD/-TKD Mutant AML in a PDX Model. Blood 140, 2022. PMID: None.
21. Akiyama H, Zhao R, Nishida Y, Baran N, Li Z, Ostermann LB, Mak PY, Ayoub E, Piya S, Carter BZ, Andreeff M, Ishizawa J. Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia. Blood 140, 2022. PMID: None.
22. Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann LB, Montoya RH, Muftuoglu M, Ruvolo VR, Mak PY, Tao W, Carter BZ, Kojima K, Daver N, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M. Enhanced p53 Activation by MDM2 and XPO1 Disrupts MYC Transcriptional Program and Profoundly Synergizes to Induce Apoptosis in Combination with BCL-2 Inhibition in Ven/HMA Resistant Acute Myeloid Leukemia. The 84th Annual meeting of the Japan Society of Hematology, 2022. PMID: None.
23. Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann LB, Heinz Montoya R, Muftuoglu M, Ruvolo VR, Mak PY, Tao W, Carter BZ, Scruggs DA, Kojima K, Daver N, Lesegretain A, Seki T, Shacham S, Konopleva M, Andreeff M. The Triple Inhibition of MDM2, XPO1 and BCL-2 Profoundly Induce Cell Kill in Ven/HMA Resistant AML. The 84th Annual Meeting of the Japanese Society of Hematology, 2022. PMID: None.
24. Akiyama H, Zhao R, Nishida Y, Ostermann LB, Mak PY, Ayoub E, Piya S, Carter BZ, Andreeff M, Ishizawa J. Synergistic Induction of Mitochondria-Regulated Ferroptotic Cell Death in Acute Myeloid Leukemia. The 84th Annual meeting of the Japan Society of Hematology, 2022. PMID: None.
25. Carter BZ, Mak PY, Tao W, Ostermann LB, Nishida Y, Boettcher S, Andreeff M. Targeting HSP90-epichaperome in TP53 mutant AML. 18th International p53 Workshop, 2022. PMID: None.
26. Carter BZ, Mak PY, Tao W, Ostermann LB, Boettcher S, Nishida Y, Ayoub E, Ruvolo V, Jabbour EJ, Hughes PE, Morrow PK, Andreeff M. Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics. Blood 138, 2021. PMID: None.
27. Chang KH, Zal T, Basyal M, Ostermann L, Muftuoglu M, Mak PY, Jia Y, Tao W, Zal A, Fogler WE, Magnani JL, Zhang W, Carter BZ, Andreeff M. Co-targeting E-selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-leukemia Therapy. Blood 138, 2021. PMID: None.
28. Carter BZ, Tao W, Ostermann L, Mu-Mosley H, Mak PY, Boettcher S, Nishida Y, Tao R, Liang E, Zhai Y, Yang D, Andreeff M. Co-targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-resistant AML Cells. Blood 138, 2021. PMID: None.
29. Nishida Y, Ishizawa J, Ayoub E, Patsilevas T, Ostermann LB, Ruvolo VR, Mak PY, Tao W, Carter BZ, Kojima K, Daver N, Lesegretain A, Seko T, Shacham S, Konopleva M, Andreeff M. Enhanced p53 Activation by Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML. Blood 138, 2021. PMID: None.
30. Carter BZ, Tao W, Mak PY, Mak D, Ostermann L, Ordentlich P, McGeehan G, Andreeff M. Menin inhibition decreases Bcl-2 and Bcl-xL and enhances venetoclax activity in NPM1/FLT3-mutated AML. SOHO, 2021. PMID: None.
31. Carter BZ, Tao W, Mak PY, Mak D, Ordentlich P, McGeehan G, and Andreeff M. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. EHA, 2021. PMID: None.
32. Muftuoglu M, Mak PY, Ruvolo V, Nishida Y, Ruvolo PP, Carter BZ, Andreeff M. High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML. Blood 136, 2020. PMID: None.
33. Yamatani K, Ai T, Saito K, Yang H, Ruvolo V, Mak PY, Kinjo S, Ikeo K, Harada H, Katayama K, Miida T, Konopleva M, Zhang W, Carter BZ, Hayashizaki Y, Andreeff M, Tabe Y. BCL2A1: A Novel Target in Refractory Acute Myeloid Leukemia with FLT3-ITD/D835 Dual Mutations. Blood 136, 2020. PMID: None.
34. Muftuoglu M, Alaniz Z, Mak D, Lin AJ, Burks JK, Carter BZ, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins. Blood 136, 2020. PMID: None.
35. Carter BZ, Mak PY, Ruvolo V, Tao W, Hughes P, Chen X, Morrow PK, Andreeff M. Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML. Blood 136, 2020. PMID: None.
36. Chen Q, Deng S, Lin Z, Deng M, Ding L, Zha J, Zhou Y, Jiang Y, Carter BZ, Xu B. Low-Dose Triptolide Promotes MDM2 Inhibitor Nutlin3a to Induce Acute Myeloid Leukemia Cell Death Via p53-Dependent and -Independent Mechanisms. Blood 136, 2020. PMID: None.
37. Carter BZ, Mak PY, Tao W, Ruvolo V, Zhang X, Nishida Y, Kornblau SM, Hughes P, Chen X, Morrow PK, Andreeff M. Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML. Blood 136, 2020. PMID: None.
38. Zhang X, Tao W, Mak P, Qi Y, Ma W, Wang J, Ruvolo V, Andreeff M, Carter BZ. Cytokine Crosstalk Within the Bone Marrow Microenvironment as a Novel Resistance Mechanism of Bcl-2/Mcl-1 Inhibitor Resistance in AML. SOHO, 2020. PMID: None.
39. Nishida Y, Ishizawa J, Ruvolo VR, Wang F, Takahashi K, Mak PY, Carter B, Andreeff M. TP73 as novel determinant of resistance to BCL-2 inhibition in acute myeloid leukemia. Blood 134, 2019. PMID: None.
40. Carter BZ, Mak PY, Kornblau S, Tao W, Nishida Y, Ruvolo V, Cidado J, Drew L, Andreeff M. TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1. Blood 134, 2019. PMID: None.
41. Yamatani K, Ai T, Saitoh K, Yang H, Suzuki K, Hori A, Murakami-Tonami Y, Zhang W, Carter BZ, Kinjo S, Ikeo K, Katayama K, Sugimoto Y, Harada H, Miida T, Shah NP, Konopleva M, Hayashizaki Y, Andreeff M, Tabe Y. CAGE transcriptome analysis reveals BCL2A1 upregulation in FLT3-ITD/D835 dual mutated AML cells harboring complex co-mutations. Blood 134, 2019. PMID: None.
42. Carter BZ, Tao W, Mak PY, Qi Z, Wang X, Kuruvilla V, Stewart C, Ruvolo V, Battula L, Konopleva M, Caenepeel S, Canon J, Hughes P, Morrow PK, Andreeff M. Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells. Blood 134, 2019. PMID: None.
43. Xu B, Y-F S, Liu L, He L, Ye J, Yuan D, Carter BZ. Combination of BCL-2 inhibition and tripolide causes synthetic lethality in acute myeloid leukemia through preventing reciprocal resistance. Blood 134, 2019. PMID: None.
44. Andreeff M, Zeng J, Soragni A, Ruvolo V, Carter BZ, Ishizawa J, Burks JK, Eisenberg D. Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia. Blood 134, 2019. PMID: None.
45. Pemmaraju N, Carter BZ, Kantarjian HM, Cortes JE, Bose P, Kadia TM, Garcia-Manero G, Bueso-Ramos C, DiNardo CD, Bledsoe S, Daver N, Popat U, Konopleva MY, Ohanian M, Pierce SA, Zhou L, Estrov ZE, Borthakur GM, Mak PY, Jain N, Jabbour E, Verstovsek S. Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood 134, 2019. PMID: None.
46. Muftuoglu M, Ruvolo V, Nishida Y, Mak PY, Ruvolo P, Carter B, Andreeff M. Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-specific Alterations and Distinct Response Patterns. Blood 134, 2019. PMID: None.
47. Carter BZ, Mak PY, Warmoes M, Tao W, Lorenzi P, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M. Inhibition of Anti-apoptotic Mcl-1 Exerts Anti-leukemia Activity through Modulation of Leukemia-stromal Interactions and Metabolic Functions in AML. Blood 134, 2019. PMID: None.
48. Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi P, Mak D, Ruvolo V, Wang X, Tan L, Cidado J, Drew L, Andreeff M. Mcl-1 Inhibition Exerts Anti-leukemia Activity and Overcomes Venetoclax Resistance in vitro and in vivo in AML through Modulation of Cell Death, Leukemia-stromal Interactions and Metabolic Functions. Cell Death Conference, Cold Spring Harbor Laboratory, 2019. PMID: None.
49. Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi P, Mak D, Ruvolo V, Wang X, Ma H, Mu H, Cidado J, Drew L, Andreeff M. Mcl-1/CDK9 Targeting by AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in vitro and in vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions. Blood 132, 2018. PMID: None.
50. Pemmaraju N, Carter BZ, Kantarjian H, Cortes J, Kadia T, Garcia-Manero G, DiNardo C, Bose P, Daver N, Konopleva M, Ohanian M, Pierce S, Zhou L, Estrov Z, Borthakur G, Salinas K, Mak PY, Jain N, Jabbour E, Verstovsek S. LCL161, An Oral Smac Mimetic/IAP antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood 132, 2018. PMID: None.
51. Zhou H, Gao Y, Wang Q, Cao R, Zhen Z, Li Q, Lin D, Zhou L, Yin C, He H, Liu X, Carter BZ, Liu Q. A Novel Oral Histone Deacetylase Inhibitor Chidamide Is Highly Effective and Well-Tolerated in Adult Early T-Cell Precursor and Ph-like Acute Lymphoblastic Leukemia. Blood 132, 2018. PMID: None.
52. Wang X, Mak PY, MaW, Su X, Hong M, Tao W, Andreeff M, Carter BZ. Targeting Wnt/β-catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML via Rac1-mediated MCL-1 inhibition. Blood 132, 2018. PMID: None.
53. Andreeff M, DiNardo C, Daver N, Kumar P, Zeng J, Nishida Y, Zernovak O, Seki T, Ishizawa J, Carter BZ. MDM2 as therapeutic target in myeloid leukemias. The 9th International MDM2 Workshop, 2018. PMID: None.
54. Tao W, Mak PY, Andreeff M, Carter BZ. Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells. Blood 130:1586, 2017. PMID: None.
55. Carter BZ, Mak PY, Wang X, Mu H, Tao W, Ruvolo V, Andreeff M. Novel ARC/IL1ß/PGE2/ß-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment and Drug Resistance in AML. Blood 130:3776, 2017. PMID: None.
56. Mu H, Konopleva M, Jacamo R, Carter BZ, McQueen T, Andreeff M. Comparison of Induction Chemotherapy in NSG and NRG Mouse Models of FLT3 Mutant AML. Blood 130:2692, 2017. PMID: None.
57. Carter BZ, Mak PY, Mu H, Mak DH, Dettman EJ, Cardone M, Wang X, Schober W, Tao W, Seki T, Andreeff M. Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML. Blood 130:4170, 2017. PMID: None.
58. Pemmaraju N, Carter BZ, Kantarjian H, Bose P, Kadia T, Jabbour E, DiNardo C, Daver N, Estrov Z, Cortes J, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle C, Piere S, Popat U, Verstovsek S. Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis. Blood 130:256, 2017. PMID: None.
59. Wang X, Mak PY, Mu H, Tao W, Pachter J, Weaver D, Xu B, Andreeff M, Carter BZ. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML. Blood 130:2653, 2017. PMID: None.
60. Carter BZ, Mak PY, Mu H, Mak DH, Dettman EJ, Cardone M, Wang X, Schober W, Tao W, Seki T, Andreeff M. Activation of p53 Enhances Antileukemia Activity of Bcr-Abl Tyrosine Kinase Inhibitors in a Murine Model of CML. 19th Annual John Goldman Conference on Chronic Myeloid Leukemia, 2017. PMID: None.
61. Carter, BZ, Mak PY, WAng X, Mu H, Ruvolo V, Andreeff M. Novel ARC/IL1ßPGE2/ß-Catenin/ARC Circuit Regulates Leukemia and Leukemia Microenvironment. ESH 2nd Scientific Workshop on Tumour Environment in Haematological Malignancies, 2017. PMID: None.
62. Pemmaraju N, Carter BZ, Kantarjian H, Bose P, Kadia T, Jabbour E, DiNardo C, Daver N, Estrov Z, Cortes J, Garcia-Manero G, Zhou L, Mak PY, Salinas K, Tuttle C, Piere S, Popat U, Verstovsek S. Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood 128:3105, 2016. PMID: None.
63. Wang X, Mak PY, Mu H, Jiang X, Mak D, Pachter JA, Weaver DT, Xu B, Andreeff M, Carter BZ. Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML. Blood 128:1574, 2016. PMID: None.
64. Jiang X, Mak PY, Mu H, Mak D, Zhang Q, Konopleva M, Andreeff M, Carter BZ. Disruption of Wnt/β-Catenin Signaling Exerts Antileukemia Activity and Sensitizes with Tyrosine Kinase Inhibitors in FLT3 Mutated AML In Vivo. Blood 128:2828, 2016. PMID: None.
65. Carter BZ, Zhou H, Mak PY, MuH, Mak DH, Zeng Z, Cortes J, Andreeff M. Combined inhibition of Beta-catenin signaling and Bcr-Abl tyrosine kinase synergistically targets blast crisis CML cells and stem/progenitor cells in vitro and in vivo. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2016. PMID: None.
66. Carter BZ, Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J, Andreeff M. Inhibition of Beta-catenin and Bcr-Abl tyrosine kinase synergistically targets blast crisis CML cells and stem/progenitor cells in vitro and in vivo. SOHO, 2016. PMID: None.
67. Pemmaraju N, Kantarjian H, Cortes J, Kadia T, DiNardo C, Estrov Z, Pierce S, Zhou L, Salinas K, Tuttle C, Mak PY, Carter BZ, Verstovsek S. Phase II Study of LCL 161, A SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF). EHA, 2016. PMID: None.
68. Jiang X, Wang Z, Yin C, Yu G, Ye J, Zhang Y, Fan Z, Xu D, Liu X, Feng R, Xu B, Sun J, Liu Q, Carter BZ, Meng F. The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients. Blood 126, 2015. PMID: None.
69. Carter BZ, Kornblau SM, Mak PY, Yang H, Qiu YH, Jiang X, Coombes K, Zhang N, Garcia-Manero G, Andreeff. Focal Adhesion Kinase As a Potential Target in AML and MDS. Blood 126, 2015. PMID: None.
70. Zhou H, Mak PY, Mu H, Mak D, Zeng Z, Cortes J, Andreeff M, Carter BZ. Synergistic Effects of Combined Targeting of Beta-Catenin/CBP and Bcr-Abl in CML Blast Crisis Stem/Progenitor Cells in Vitro and in Vivo as Analyzed By Single Cell Mass Cytometry (CyTOF). Blood 126, 2015. PMID: None.
71. Jiang X, Mak PY, MU H, Zhang W, Mak D, Puvolo P, McQueen T, Zhou H, Cortes JE, Andreeff M, Carter BZ. Concurrent Inhibition of Beta-Catenin/CBP and FLT3 Strongly Suppresses c-Myc and Synergistically Induces Apoptosis in FLT3 Mutant AML Cells. Blood 126, 2015. PMID: None.
72. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting Of Bcl-2 And Bcr-Abl Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem/Progenitor Cells. 17th Annual John Goldman Conference on CHRONIC MYELOID LEUKEMIA: Biology and Therapy, 2015. PMID: None.
73. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting Of Bcl-2 And Bcr-Abl Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem/Progenitor Cells. SOHO, 2015. PMID: None.
74. Ruvolo PP, Battula VL, Qui YH, Ruvolo VR, Jacamo R, Zeng Z, R-Y W, McQueen T, Rao A, Yoo SY, Le PM, Hail N, Carter BZ, Kornblau SM, Andreeff M. Reverse Phase Protein Analysis of Mesenchymal Stem Cells from AML Patients and Healthy Donors Reveals Distinct Patterns of Protein Expression Reflecting Differences in Senescence, Differentiation and Survival Signaling. Blood 124, 2014. PMID: None.
75. Borthakur G, Foran JM, Wang ES, Rakkar A, Hager S, Frey NV, Andreeff M, Garcia-Manero G, Kadia TM, Carter BZ, Minderman H, Russell L, Tibes R. A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis. Blood 124, 2014. PMID: None.
76. Zhou H, Mak PY, Mu H, Mak DH, Kouji H, Cortes J, Konopleva M, Andreeff M, Carter BZ. Combination of Tyrosine Kinase Inhibitor with β-Catenin/CBP Modulator C82 Reverses TKI Resistance, Eradicates Quiescent CML Stem/Progenitors Cells, and Overcomes MSC-Associated Microenvironmental Protection. Blood 124, 2014. PMID: None.
77. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Konopleva M, Cortes J, Andreeff M. Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells. Blood 124, 2014. PMID: None.
78. Mak PY, Kornblau S, Qiu Y, Wei W, Kouji H, Coombes K, Cortes J, Andreeff M, Carter BZ. Disrupting Wnt/ß-Catenin Signaling By a ß-Catenin/CBP Modulator C-82 Suppresses Cell Growth and Induces Apoptosis in AML Blasts and CD34+38- AML Progenitor Cells. Blood 124, 2014. PMID: None.
79. Carter BZ, Mak PY, Mak DH, Schober W, McQueen T, Konopleva M, Cortes J, Andreeff M. p53 Activation via MDM2 Blockade with Nutlin3a Sensitizes Primary Blast Crisis Chronic Myeloid Leukemia Cells and Stem/Progenitor Cells to ABT-737- and Nilotinib-induced Apoptosis. 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2014. PMID: None.
80. Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Cortes J, Kantarjian H, Konopleva M, Andreeff M. Combined Targeting Of Bcl-2 And Bcr-Abl Tyrosine Kinase Eradicates Chronic Myeloid Leukemia Stem/Progenitor Cells. 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2014. PMID: None.
81. Carter BZ, Mak PY, Mak DH, Kojima K, Dilip A, Ruvolo V, Jacamo R, Andreeff. Tumor Suppressor p53 is Antagonized by ARC (apoptosis repressor with caspase recruitment domain) in AML. 16th International p53 Workshop, Stockholm, 2014. PMID: None.
82. Cortes JE, Carter BZ, Quintas-Cardama A, Inada T, Morita K, Fujimori M, Kouji H, Mak PY, Ruvolo V, Borthakur G, Andreeff M, Konopleva M, Ravandi F, Kantarjian H. A Phase I Dose-Escalation Study OF PRI-724, A CBP/B-Catenin Modulator In Patients With Advanced Acute Myeloid Leukemia (AML). EHA Conference, Milano Italy, 2014. PMID: None.
83. Mak PY, Mak DH, Kojima K, Dilip A, Ruvolo V, Jacamo R, Andreeff M, Carter BZ. ARC Suppresses Cell Death By Antagonizing p53 Function and Suppressing TRAIL In AML Cells. Blood 122, 2013. PMID: None.
84. Ishizawa J, Kojima K, Dilip A, Ruvolo V, Carter BZ, Allen JE, Neelapu SS, McDonnell T, Talekar M, El-Deiry WS, Kwak LW, Andreeff M. ONC201 exerts p53-independent cytotoxicity through TRAIL and DR5 induction in mantle cell lymphomas. Blood 122, 2013. PMID: None.
85. Carter BZ, Mak PY, Mak DH, Konopleva M, Cortes J, Andreeff. Activation Of p53 By MDM2-Inhibition Sensitizes Quiescent Blast Crisis CML Stem/Progenitor Cells To Bcl-2 Inhibitor- and Tyrosine Kinase Inhibitor-Induced Cell Death. Blood 122, 2013. PMID: None.
86. Carter BZ, Mak PY, Chen Y, Jacamo R, Ruvolo V, Andreeff M. ARC supports leukemia-stromal interactions by regulating multiple receptor-chemokine axes in AML. Blood 122, 2013. PMID: None.
87. Andreeff M, R-Y W, Davis E, Jacamo R, Ruvolo P, McQuee T, Huang X, Battula VL, Chen Y, Majumdar S, Benito JM, Zeng Z, Benton C, Carter B, Mu H, Ma W, Ruvolo V, Hodgson L, Konoplev S, Pan R, Somanchi A, Strunck D, Zhang Q, Kornblau SM, Kantarjian H, Marcucci G, Garzon R, Zuber J, Lowe S, Croce C, Konopleva M. Proteomic, gene expression, and micro-RNA analysis of bone marrow mesenchymal stromal cells in acute myeloid leukemia identifies pro-inflammatory, pro-survival signatures in vitro and in vivo. Blood 122, 2013. PMID: None.
88. Carter BZ, Mak PY, Chen Y, Jacamo R, Ruvolo V, Mak DH, McQueen T, Konopleva M, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in vitro and in vivo by Regulating Leukemia-Stroma Interactions. Blood 120, 2012. PMID: None.
89. Mak PY, Mak DH, Shi Y, Ruvolo V, Jacamo R, Andreeff M, Carter BZ. ARC Is Regulated by MAPK and PI3K and Confers Drug Resistance and Survival Advantage to AML in vitro and in vivo. Blood 120, 2012. PMID: None.
90. Carter BZ, Mak PY, Mak DH, Ruvolo V, Jacamo R, Kornblau SM, Andreeff M. Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML. Blood 120, 2012. PMID: None.
91. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Kornblau S, McQueen T, Weng D, Burns J, Andreeff M. Antagonizing IAPs by SMAC Mimetic Birinapant Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy in vitro and in vivo. Hematologic Malignancies 2012, 2012. PMID: None.
92. Mak PY, Mak DH, Shi Y, Ruvolo V, Jacamo R, Andreeff M, Carter BZ. ARC Is Regulated by MAPK and PI3K and Confers Drug Resistance and Survival Advantage to AML in vitro and in vivo. Hematologic Malignancies 2012, 2012. PMID: None.
93. Carter BZ, Qiu Y, Huang X, Dia L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes JE, Kantarjian HM, Andreeff M, Kornblau SM. Survivin Is Highly Expressed in AML Stem Cells and Predicts Poor Clinical Outcome. Blood 118(21):108-109, 2011. PMID: None.
94. Carter BZ, Mak DH, Piu Y, Kornblau SM, Mak PY, Weng D, McKinlay MA, Andreeff M. Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy. Blood 118(21):32, 2011. PMID: None.
95. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML. Blood 118(21):672, 2011. PMID: None.
96. Mak DH, Manton C, Andreeff M, Carter BZ. SMAC-Mimetic BV-6 Sensitizes Therapeutic Agents-Induced Apoptosis In AML Cells. Blood 116(21), 2010. PMID: None.
97. Carter BZ, Mak DH, Schober WD, Konopleva M, Cortes J, Kantarjian H, Koller E, Huang Z, Reed JC, Andreeff M. Targeting XIAP and ARC (apoptosis repressor with caspase recruitment domain) Overcomes Imatinib Resistance in Blast Crisis CML Cells. Blood 116(21), 2010. PMID: None.
98. Carter BZ, Zhang N, Coombes KR, Mak DH, Qiu Y, Thomas DA, Ravandi F, Kantarjian H, Andreeff M, Kornblau SM. Expression of apoptosis repressor with caspase recruitment domain (ARC), an antiapoptotic protein, is strongly prognostic in acute myeloid leukemia (AML). Blood 114, 2009. PMID: None.
99. Mak DH, Schober WD, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ. Inhibition of Bcl-2/Bcl-XL promotes apoptosis in blast crisis CML including quiescent primitive progenitor cells regardless of cellular responses to tyrosine kinase inhibitors. Blood 114, 2009. PMID: None.
100. Schimmer AD, Estey EH, Borthakur G, Carter B, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Jacob C, Morris S, Jolivet J, Andreeff M. Phase 1/2 trial of the XIAP antisense oligonucleotide (AEG35156) in combination with idarubicin and cytarabine in patients with relapsed/refractory AML. Blood 112:764, 2008. PMID: None.
101. Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 112:1941, 2008. PMID: None.
102. Carter BZ, Mak DH, Morris S, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian HM, Andreeff M. Pharmacodynamic study of Phase 1/2 trial of the XIAP antisense oligonucleotide (AEG35156) in combination with chemotherapy in patients with relapsed/refractory AML. Blood 112:1943, 2008. PMID: None.
103. Carter BZ, Mak DH, Schober WD, Woessner R, Gross S, Harris D, Estrov Z, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Blood 110(11):819A, 2007. PMID: None.
104. Mak DH, Schober WD, Chen W, Cortes JE, Kantarjian HM, Andreeff M, Carter BZ. Triptolide induces cell death independent of cellular responses to Imatinib in blast crisis CML cells and sensitizes Imatinib. Blood 110(11):481a, 2007. PMID: None.
105. Carter B, Kim T K, Duncan M, Wei H, Pinilla C, Reed J, Andreeff M. AML progenitor/stem cells overexpress XIAP are sensitive to the small molecular XIAP inhibitor 1396-11. Blood 108:2586, 2006. PMID: None.
106. Carter B, Mak D, Schober W, Dietrich M, Pinilla C, Reed J, Andreeff M. Triptolide Sensitizes Leukemia Cells to TRAIL Induces Apoptosis via Decreases of XIAP and p53-mediated Increase of DR5. Blood 108:528, 2006. PMID: None.
107. Carter B, Mak D, Schober W, Koller E, Dean N, Marcusson E, Monia B, Andreeff M. Inhibiting Mcl-1 with an antisense oligonucleotide induces cell death in acute myeloid leukemia cells. Proc Am Assoc Cancer Res 47:4075, 2006. PMID: None.
108. Carter BZ, Kim TK, Mak DH, Hu W, Pinilla C, Reed JC, Andreeff M. AML progenitor/stem cells overexpress XIAP are sensitive to the small molecular XIAP inhibitor 1396-11. Blood 108 (11):2586, 2006. PMID: None.
109. Carter B, Mak D, Schober W, Heller J, Andreeff M. Tetra-O-methyl nordihydroguaiarectic acid inhibits growth and induces death of leukemia cells independent of Cd2 and survivin. Blood 108:4366, 2006. PMID: None.
110. Carter BZ, Mak D, Schober W, Koller E, Dean NM, Andreeff M. Simultaneous inhibition of Mcl-1 and XIAP to induce apoptosis in AML cells. Blood 106:1520, 437a, 2005. PMID: None.
111. R-Y W, Carter BZ, Tsao T, Schober W, McQueen T, Konopleva M, Andreeff M. The role of apoptotic inducing factor (AIF) in acute myeloid leukemia (AML). Blood 106:2369, 666a-667a, 2005. PMID: None.
112. Carter BZ, Mak D, Shi Y, Schober WD, Wang R, McQueen T, Konopleva M, Koller E, Dean NM, Andreeff M. Regulation and targeting of Eg5 in blast crisis CML: overcoming Imatinib resistance. Blood 106:2877, 806a, 2005. PMID: None.
113. Schimmer AD, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Houghten R, Brandwein J, Minden MD, Schuh A, Wells RA, Messner H, Reed JC, Carter BZ. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of leukemia cell lines and patient samples. Blood 104:759, 217a, 2004. PMID: None.
114. Carter BZ, Schober WD, McQueen T, Evans RL, Andreeff M. Triptolide-induced apoptosis is dependent on caspase activation and NFkB signaling and mediated by XIAP and Survivin downregulation through the mitochondrial pathway in leukemic cells. Blood 104:3394, 926a, 2004. PMID: None.
115. Zeng Z, Konopleva M, Estrov Z, Hu W, Carlson-Bremer D, Harris D, Carter BZ, Milella M, Lu Y, Mills GB, Andreeff M. Inhibition of AKT signaling by a small molecule KP372-1 induces apoptosis in AML. Proc Am Assoc Cancer Res 45:3981, 2004. PMID: None.
116. Milella M, Konopleva M, Tabe Y, Precupanul C, Gregorj C, Carter BZ, Kornblau SM, Cognetti F, Tafuri A, Andreeff M. MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis. Blood 102:2194, 595a, 2003. PMID: None.
117. Carter BZ, Schober WD, McQueen T, Andreeff M. Regulation of Survivin expression through bcr-abl/MAPK cascade: Survivin as a therapeutic target in STI571 resistant CML cells. Blood 102:2406, 651a, 2003. PMID: None.
118. Konopleva M, Hu WX, Lu Y, Carter BZ, Mills GB, Andreeff M. Inhibition of AKT signaling induces apoptosis in myeloid leukemia. Proc Am Assoc Cancer Res 44:5544, 1271, 2003. PMID: None.
119. Carter BZ, Milella M, R-Y W, Schober WD, Chism D, Andreeff M. Targeting surviving expression induces G2/M block and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Proc Am Assoc Cancer Res 44:103, 23, 2003. PMID: None.
120. Konopleva M, Hu W, Carlson-Bremer D, Zeng Z, Carter BZ, Milella M, Lu Y, Mills GB, Andreeff M. Inhibition of AKT signaling by a small molecule KP372-1 induces apoptosis in AML. Blood 102:4757, 258b, 2003. PMID: None.
121. Carter BZ, Milella M, Schober WD, Chism D, Andreeff M. Targeting Survivin expression induces G2/M block and subsequent cell death in myeloid leukemic cells. Blood 100:4612, 270b, 2002. PMID: None.
122. Hu W, Konopleva M, Lu Y, Carter BZ, Mills GB, Andreeff M. New Akt inhibitor KP-302 induces apoptosis in myeloid leukemia. Blood 100:4607, 269b, 2002. PMID: None.
123. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari AM, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways: a promising new therapeutic strategy for acute myelogenous leukemia. 54th Annual Symposium on Fundamental Cancer Research: Mechanisms for Cell Growth and Differentiation, Houston, TX, 2001. PMID: None.
124. Carter BZ, Milella M, Kornblau SM, Schober WD, Tsao T, Contreras P, Reed JC, Andreeff M. Expression and regulation of XIAP in acute myeloid leukemia by MAPK and PI3K signaling. Blood 98:3170, 761a, 2001. PMID: None.
125. Andreeff M, Konopleva M, Zhao S, Leysath C, Carter B, Milella M, Weidner D, Lapillonne H, Tabe Y, Schober W, Hu W, Heiss P, Estey E, Huang Z, Kornblau S. Dysregulation of apoptosis in AML: New therapeutic opportunities. Ann Hematol 20:38, S10, 2001. PMID: None.
126. Milella M, Estrov Z, Kornblau SM, Konopleva M, Tari AM, Carter BZ, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M. Synergistic induction of apoptosis by simultaneous disruption of the bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 98:3490, 840a, 2001. PMID: None.
127. Carter BZ, Milella M, Tsao TY, Wathen JK, Altieri DC, Andreeff M. Expression and regulation of survivin in acute myeloid leukemia (AML): Through MEK/ERK and PI3K pathways. Blood 96:#1986, 461a, 2000. PMID: None.
128. Milella M, Estrov Z, Carter BZ, Harris D, Sebolt-Leopold J, Andreeff M. The MEK/ERK kinase module: a potential new target for AML therapy. Blood 96:#514, 120a, 2000. PMID: None.

Book Chapters

1. Carter BZ, Andreeff M. IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia. In: Targeted Therapy of Acute Myeloid Leukemia. None. None, 2015.
2. Samudio I, Konopleva M, Carter B, Andreeff M. Apoptosis in Leukemias: Regulation and Therapeutic Targeting. In: Acute Myelogenous Leukemia: Genetics, Biology and Therapy. None. Springer Science + Business Media, LLC, 2009.

Letters to the Editor

1. Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, Ordentlich P, McGeehan GM, Andreeff M. Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica 108 No.9, 2023.
2. Hail N, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis 11: 889-904, 2006.